Identification of the
. A single mutational event may account for most CF mutations in Northern European populations (12) ; another mutation appears to be prevalent in some Southern European populations (15) . Additional haplotype data indicate that there could be several other mutations (15, 16, 19, 20) . The two clinical subgroups of CF patients, those with pancreatic insufficiency (CF-PI) and those with pancreatic sufficiency (CF-PS), can be explained by different mutations on the basis of family studies (18) and haplotype data (19, 20) . Patients with CF-PI, which constitute the larger proportion (about 85 percent) of the CF population, appear to be genetically more homogeneous than those with CF-PS (about 15 percent); most individuals with CF-PS appear to be compound heterozygotes (19) . We must emphasize, however, that these studies were based on linked DNA markers whose exact relation to CF was not entirely certain. Further understanding of the pathophysiology, haplotype association, and population distribution of CF would require detailed molecular knowledge about the mutations.
The extensive genetic and physical mapping data made it possible for molecular cloning studies to be focused on a small segment of DNA on chromosome 7 (12, 13, 17, 21, 22). A putative CF gene has now been identified through chromosome walking and jumping (23) and cDNA clones have been isolated and characterized (24) . Because of the lack of chromosome deletions and rearrangements in CF and the lack of a well-developed functional assay for the CF gene product, the identification of the CF locus required a detailed characterization of the locus itself and comparison between the CF and normal (N) alleles. Random, phenotypically normal, individuals could not be included as controls in the comparison because of the high frequency of symptomless carriers in the population. As a result, only parents of CF patients, each of whom by definition carries an N and a CF chromosome, were suitable for the analysis. Moreover, because of the strong allelic association observed between CF and some of the closely linked DNA markers (12-15, 21), it was necessary to exclude the possibility that sequence differences detected between N and CF were polymorphisms associated with the disease locus.
Identification of RFLP's and family studies. To determine the relation of each of the DNA segments isolated from the chromosome walking and jumping experiments to CF, restriction fragment length polymorphisms (RFLP's) were identified and used to study families where crossover events between CF and other flanking DNA markers had previously been detected (25, 26) . In all, 18 RFLP's were detected in the 500-kb region of chromosome 7; 17 of them (from E6 to CE 1.0) are listed in Table 1 ; some of them corresponded to markers previously reported (12, 13). Five of the RFLP's were identified with cDNA and genomic DNA probes derived from the putative CF locus, namely 10-1X.6, T6/20, H1.3, and CE1.0 (23, 24). The RFLP data (Table 1) are presented with markers in the regions of MET and D7S8 included for comparison. The physical distances between these markers as well as their relation to MET and D7S8 are shown in Fig. 1 .
Because families with informative crossovers only gradually became available [through the courtesy of investigators (27) ] over the course of the study, not all the DNA markers were examined in these families (28) . The recombination breakpoints were localized for the two families [out of four that showed a crossover between D7S23 and CF (26)] that were informative for the DNA markers tested. One of them showed a crossover between the sites defined by JG2E1 (also known as KM19) and E2.6 (29) , and the other between JG2E1 and E4.1 (Mp6d.9) (30) (Fig. 1) . These results indicated that CF mapped to the telomeric side of JG2E1. The two other families were not informative in the analysis. Only a single 1074 family (SLC1380) was documented to show a recombination event between CF and D7S8 (25), and more recently the crossover point was narrowed to between CF and D7S424, a jump clone derived from D7S8 (31); no crossover was detected with the abovedescribed DNA markers in this family. CF was therefore delimited to the region between JG2E1 and D7S424, spanning less than 900 kb (Fig. 1) . Because of the small number of recombinant families available for the analysis, which was expected from the close distance between the markers and CF, and because of the possibility of misdiagnosis, alternative approaches were necessary in further fine mapping of the CF locus.
Allelic association. Allelic association (linkage disequilibrium) has been detected for many closely linked DNA markers (32, 33) . Although the utility of using allelic association for measuring genetic distance is uncertain, an overall correlation has been observed between CF and the flanking DNA markers. A strong association with CF was noted for the closer DNA markers D7S23 (12, 14) and D7S122 (13), whereas little or no association was detected for the more distant markers MET, D7S8, or D7S424 (21, 31; Fig. 1 ).
The degree of association between DNA markers and CF (as measured by the Yule's association coefficient) increased from 0.35 for metH and 0.17 for J32 to 0.91 for 10-IX.6 [only CF-PI families were used in the analysis as they appeared to be genetically more homogeneous than CF-PS (19)]. The association coefficients appeared to be rather constant over the 300-kb interval between EGI.4 and H1.3; the fluctuations detected at several locations, most notably at H2.3A, E4.1, and T6/20, were probably due to the variation in the allelic distribution among the N chromosomes (Table 1) . These data are therefore consistent with the result from the study of recombinant families (Fig. 1) . A similar conclusion could also be made by inspection of the extended DNA marker haplotypes associated with the CF chromosomes (as discussed below). However, the strong allelic association detected over the large physical distance between EG1.4 and H1.3 did not allow further refined mapping of the CF locus. Since J44 was the last genomic DNA clone isolated by chromosome walking and jumping before a cDNA clone was identified (24), the strong allelic association detected for the JG2E1-J44 interval prompted us to search for candidate gene sequences over this entire interval. The highest degree of allelic association was in fact detected between CF and the two RFLP's detected by 10-1X.6, a region near the major CF mutation.
Strong allelic association was also detected among subgroups of RFLP's on both the CF and N chromosomes, namely, between adjacent markers E6 and E7, between pH131 and W3D1.4, between the Acc I and Hae III polymorphic sites detected by 10-1X.6 and among EG1.4, JG2E1, E2.6 (E.9), H2.8, and E4.1 (34). The two groups of distal markers in the MET and D7S8 regions also showed some degree of linkage disequilibrium among themselves, but they showed little association with markers from E6 to CELO, consistent with the distant locations for MET and D7S8. The lack of association between DNA markers that are physically close may indicate the presence of recombination hot spots (33, 34). Examples of these potential hot spots are the region between E7 and pH131, around H2.3A, and between J44 and the regions covered by the probes 10-1X.6 and T6/20 ( Fig. 1 ). These regions, containing frequent recombination breakpoints, were useful in the subsequent analysis of extended haplotype data for the CF region.
The major CF mutation. Molecular cloning experiments have allowed us to identify a gene in the J44-D7S424 interval (23, 24 To investigate the proportion of CF patients carrying this deletion (AFso8), we used genomic DNA samples from patients and their parents. Each sample was amplified with oligonucleotide primers flanking the mutation in a polymerase chain reaction (PCR) (35) and hybridized to 32P-labeled oligonucleotides specific for the normal and the putative mutant sequences (Fig. 2) . The result of this analysis showed that 68 percent (145/214) of CF chromosomes in the general patient population had the AF508 mutation (Table 2 ). In contrast, none (0/198) of the N chromosomes had the deletion (Table 2 ) (X2 = 207, P < 10-57.5!), suggesting that this sequence alteration is specific to CF and that it is the major mutation causing the disease. No recombination has been detected between the AF508 mutation site and CF. However, the possibility that this sequence difference corresponded to a tightly linked DNA polymorphism had yet to be excluded.
Haplotype analysis. Extended haplotypes based on 23 DNA markers were generated for the CF and N chromosomes in the collection of families previously used for linkage analysis (36) . Assuming recombination between chromosomes of different haplotypes, it was possible to construct several lineages of the observed CF chromosomes and, also, to predict the location of the disease locus (34, 37). To obtain further information useful for understanding the nature of different CF mutations, AF508 was correlated with the extended DNA marker haplotypes (37). Five major groups of N and CF haplotypes could be defined by the RFLP's within or immediately adjacent to the putative CF locus (regions 6 to 8) (Table 3) . Most recombinations between haplotypes occurred between regions 1 and 2 and between 8 and 9, again in good agreement with the relatively long physical distance between these regions. Other less frequent breakpoints occurred between short distance intervals, and they generally corresponded to the hot spots identified by pairwise allelic association studies (34) . A striking result of our study is that AF508 associated almost exclusively with group I, the most frequent CF haplotype, consistent with our hypothesis that this deletion constitutes the major mutation in CF. More important, while AF508 was detected in 89 percent (62/70) of the CF chromosomes with the AA haplotype (corresponding to regions 6 and 7 flanking the deletion), no deletions were found in the 14 N chromosomes within the same group (X2 = 47.3, p < 10-4). The AF508 mutation is therefore not a common sequence polymorphism associated with the core of the group I haplotype ( Table 3) .
One of the CF chromosomes, detected by the specific oligonucleotide probe for AF508, belonged to a different haplotype group (group III). None of the nine other CF chromosomes or 17 N chromosomes within group III hybridized to the probe. This specific hybridization result suggests that the mutation harbored on this chromosome is similiar to AF508. Although recombination or gene conversion are possible mechanisms to explain the presence of this deletion on a haplotype that did not belong with group I, it is more likely that this group III chromosome represents a recurrent mutation event, a situation similar to the s and 1E mutations at the 3-globin locus (38) . Together, the results of the oligonucleotide hybridization study and the haplotype analysis provide a strong indication that the gene locus described above is the CF locus and that the 3-bp deletion (AF508) is the most common mutation in CF.
Other CF mutations. Haplotype association with specific mutations has been demonstrated in studies of other genetic disorders (39) . As indicated by these examples, knowledge of the haplotypes associated with the disease chromosomes facilitates studies on the molecular defects of each of the respective mutations.
The association of AF508 with one common and one rare CF haplotype provided further insight into the number of mutational events that could contribute to the present patient population. On the basis of the extensive haplotype data, the two original chromosomes in which the AF508 mutation occurred are likely to carry the haplotype -AAAAAAA-(group Ia) and -CBAACBA-(group Ila), as defined (Table 3) . The other CF chromosomes in group I carrying the deletion are probably recombination products derived from the original chromosome. If the CF chromosomes in each haplotype group are considered to be derived from the same origin, only three to four additional mutational events would be predicted (Table 3) ; however, since many of the CF chromosomes in the same group are different from each other, further subdivision within each group is possible. As a result, a greater number of independent mutational events can be considered, and the data suggest that at least seven additional, putative mutations also contribute to the CF-PI phenotype. The mutations leading to the CF-PS subgroup are probably more heterogeneous and are considered below.
The to be defined, none of these mutations severely affect the region corresponding to the oligonucleotide binding sites used in the PCRhybridization experiment (Fig. 2 and legend) .
Pancreatic sufficiency. CF-PS is defined clinically as sufficient pancreatic exocrine function for digestion of food; however, the level of residual pancreatic enzyme activity varies among patients (1, 40). Our previous haplotype data suggested that the CF-PI and CF-PS patients have different mutant alleles (19) . Although the basic biochemical defect in CF has yet to be defined, it is possible that the residual pancreatic enzyme activity in CF-PS patients is a direct reflection of the activity of the mutant CF gene product. Thus, the residual exocrine function conferred by a mild (CF-PS) allele, although much lower than that of the normal gene product, would constitute a dominant phenotype over that of more severe (CF-PI) mutations with little or no function. Therefore, only patients carrying two copies of severe alleles would be CF-PI and patients carrying one or two mild alleles would be CF-PS.
To test this hypothesis, we used the information on the proportion of CF patients carrying the AF508 deletion. If we assume that a severe mutation is recessive to a mild mutation and a distribution of CF alleles among the patient population according to the Hardy-
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Weinberg law, the frequency could be estimated to be -0.92 for the severe alleles and -0.08 for the mild alleles (M) ( Table 4 ). Since most CF-PI patients were homozygous for AF508, it was reasonable to assume that this mutation corresponded to one of the severe alleles. Given the observed frequency of AF508 (0.68) in the studied CF population (Table 2) , the frequency of the remaining severe alleles could be derived. The proportion of AF508AF508, SS, MM, AF508S, AF508M, and SM patients was then calculated. Since individuals with SM and MM could not be distinguished phenotypically or genotypically, they were combined in the analysis. The observed frequencies for all five groups of patients were as expected from this hypothesis ( Table 4) .
The above analysis thus provides strong support for our hypothesis that CF-PI is due to the presence of two severe alleles and that a CF-PS patient carries either a single severe allele or two mild alleles. This model also explains the lower frequency of AF508 in the CF-PS than in the CF-PI population and the excess number of CF-PS patients with one copy of the deletion (Table 4) .
Given the predicted dominant phenotype conferred by the M alleles, it was necessary to examine the CF chromosomes in CF-PS patients individually in order to identify those carrying the M alleles. Five of the seven representative CF-PS patients carry one copy of the AF508 deletion; at least five different haplotypes could be assigned to the other CF chromosomes (Table 5 ). These latter observations further support our previous suggestion that the majority of CF-PS patients are compound heterozygotes (19) . Further delineation of these and other CF haplotypes observed in our study would require a larger patient population or a more detailed characterization of CF mutations (or both).
Meconium ileus (MI), which occurs in 5 to 10 percent of newborns with CF, is generally ascribed to failure of pancreatic enzyme secretion and digestion of intraluminal contents in utero (1). Although only six patients were identified to have MI in our study (41) , all of them belong to the CF-PI subgroup, five of them homozygous and one heterozygous for AF508 (Table 5) . It is therefore tempting to speculate that homozygous AF508 (or equivalent severe mutations) may be a prerequisite for development of MI. Moreover, since MI only occurs in a small proportion of CF patients and with only 30 percent concordance within families (42) , it is probable that this condition is also determined by other genetic or nongenetic factors.
Implications for genetic diagnosis. Previous DNA-based genetic testing for CF has only been available to families with affected children and to their close relatives (14, 43 Table  3 .
CF-PS
tAllele designations are the same as Table 4. percent of CF patients without a previous family history can be accurately diagnosed by DNA analysis, and 68 percent of the CF carriers in the population can be identified with a probe specific for the AF508 mutation. It will be necessary to define most of the existing CF mutations before an effective DNA-based genetic testing program can be implemented at the population level. Since the AF508 mutation constitutes about 68 percent of all CF mutations, RFLP analysis may be used to supplement genetic diagnosis by direct deletion detection. About 55 percent of the CF parents not carrying the AF508 mutation are expected to be informative for the DNA marker JG2E1 based on retrospective analysis of our CF linkage families (36); an additional 39 percent would be informative if E6 (Taq I) and J3.11(Msp I) were also tested; virtually all parents would be informative if H2.3A (XV2C-Taq I), E2.6(E.9-Msp I), E4.1 (Mp6d.9-Msp I), J44 (Xba I), and metD (Ban I) were included. Clearly, more accurate and simple testing procedures will be developed when additional CF mutations are identified.
As indicated above, variation of DNA marker haplotype association in CF has been detected among different European populations (9, 15). Whether the haplotype classifications proposed here correlate with geographic distributions remains to be determined. Our preliminary study showed that all seven CF chromosomes in group Ib (Table 3) were from individuals of French-Canadian ancestry (44). It is unexpected that at least two independent mutational events had occurred on a haplotype (groups Ia and Ib) that is rare among the N chromosomes. A detailed description of such haplotypes would be usefull for understanding the high incidence of CF in the Caucasian population (44) and for further mutational analysis. Further, a complete molecular description of all the CF mutations should provide important insight into the pathophysiology of the 8 SEPTEMBER 1989 disease and form the basis for the development of improved treatment.
